Targeting leukemia stem cells in acute myeloid leukemia
Therapeutic Targeting of Human AML Stem Cells
Researchers are developing treatments that attack leukemia stem cells to help people with acute myeloid leukemia (AML).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11176372 on NIH RePORTER |
What this research studies
This project looks for common features of leukemia stem cells (LSCs) so treatments can target the root of AML. The team studies patient leukemia samples and laboratory models to understand LSC metabolism and how blocking the BCL2 pathway shuts down energy production in these cells. Early clinical work with BCL2 inhibitors has helped many newly diagnosed patients, but relapses still occur. Researchers are studying how resistance emerges and testing new strategies to overcome it.
Who could benefit from this research
Good fit: People with acute myeloid leukemia — especially newly diagnosed patients or those who have relapsed after prior therapy — would be most relevant for this research.
Not a fit: Patients without AML or those who are medically ineligible for targeted or experimental treatments are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could produce therapies that better eliminate the cells that cause relapse, improving remission duration and survival.
How similar studies have performed: BCL2 inhibitors have already shown strong activity in newly diagnosed AML patients, though relapse after initial response remains a challenge.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Jordan, Craig T. — University of Colorado Denver
- Study coordinator: Jordan, Craig T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.